Ginkgo Biloba Leaf Extract (GBE): A Comprehensive Monograph on its Phytochemistry, Pharmacology, Clinical Evidence, and Safety

I. Introduction: The Living Fossil in Modern Medicine

A. Botanical Profile and Unique Biological Status of Ginkgo biloba

The Ginkgo biloba tree stands as a singular entity in the botanical world, a true "living fossil" that offers a window into the planet's deep past.[1] It is the sole surviving species of the division Ginkgophyta, an ancient lineage of plants that first appeared over 270-290 million years ago during the Permian period.[4] Fossils nearly identical to the modern tree date back to the Middle Jurassic, approximately 170-200 million years ago, indicating that this species has remained remarkably unchanged while dinosaurs rose and fell, and continents drifted.[6] This extraordinary longevity and resilience make it an object of profound scientific and cultural interest.

Morphologically, the tree is a deciduous gymnosperm, capable of reaching heights of up to 40 meters (130 feet) and living for over a thousand years.[3] Its most distinctive feature is its unique, fan-shaped leaf, which is unlike that of any other seed plant.[8] The leaves, typically 5-10 cm long, exhibit dichotomous venation, where veins radiate from the base and repeatedly fork into two, but never form a network.[10] This structure gives rise to the species name biloba, referring to the frequent notch that divides the leaf into two lobes.[3] The resemblance of its leaves to the pinnae of the maidenhair fern (Adiantum capillus-veneris) has earned it the common name "maidenhair tree".[8] In autumn, the leaves turn a brilliant saffron or golden yellow, often falling in a short span of one to fifteen days, creating a striking visual display.[8]

The reproductive biology of Ginkgo biloba is also primitive and noteworthy. The species is dioecious, meaning individual trees are either male or female.[3] Male trees produce small, pollen-producing cones, while female trees, after wind pollination, produce ovules that develop into seeds.[3] These seeds are often mistaken for fruits; they consist of a soft, fleshy outer layer (sarcotesta) and a hard inner shell (sclerotesta).[8] The sarcotesta of the mature seed contains butyric acid, the same compound found in rancid butter, which emits a notoriously pungent and unpleasant odor upon decomposition.[3] Consequently, male trees are almost exclusively planted in urban and horticultural settings to avoid the mess and smell associated with the female seeds.[3]

The tree's remarkable resilience is not merely historical but practical. It is highly resistant to pests, diseases, and air pollution, making it an ideal street tree in urban environments.[3] Its most profound testament to survival is the endurance of several ginkgo trees located within 1-2 kilometers of the hypocenter of the 1945 atomic bomb blast in Hiroshima, Japan. While the surrounding temples and buildings were obliterated, these trees survived, budded out the following spring, and continue to thrive today, becoming powerful symbols of hope, peace, and endurance.[4]

B. Historical Trajectory: From Ancient Use in Traditional Chinese Medicine to a Global Phytopharmaceutical

The modern history of Ginkgo biloba is a story of preservation and rediscovery. Once widespread across the Northern Hemisphere, the genus was nearly driven to extinction during the ice ages, surviving only in a few isolated pockets in eastern China, particularly in the Tianmu Shan mountains.[7] It was likely saved from complete extinction through cultivation by Buddhist monks in temple and monastery gardens, where it was revered as a sacred tree.[3] This sacred status ensured its survival and propagation over centuries.

The earliest written records of human cultivation date back approximately 1,000 years to the Song Dynasty in China (circa 1000 CE).[7] These early texts refer to it as a "nut tree," cultivated for its edible seeds, which were called "silver apricot" or "white fruit".[7] Beyond its culinary use, the ginkgo seed found a prominent place in Traditional Chinese Medicine (TCM). It was first recorded as a medicinal plant in the Shen Nong Ben Cao Jing approximately 2,000 years ago.[16] Medical texts from later dynasties, such as the Qing (1644–1911 CE), document the use of various parts of the tree, primarily the seeds, to treat a range of ailments including cough, asthma, bronchitis, digestive issues, and urinary problems.[1]

The tree remained unknown to the Western world until the late 17th century. In 1691, the German botanist and physician Engelbert Kaempfer, stationed with the Dutch East India Company in Japan, encountered the tree in a temple garden.[4] He documented it in his 1712 work Amoenitates Exoticae, introducing the name "Ginkgo" to Western science—a name now believed to be a transcription error of the Japanese pronunciation ginkyō.[8] Living specimens were introduced to Europe in the mid-18th century and to North America by 1784, initially as an ornamental curiosity.[6]

The transition of Ginkgo biloba from an ornamental tree and a component of TCM to a global phytopharmaceutical began in the 1960s. A group of German scientists at Dr. Willmar Schwabe Pharmaceuticals began investigating the pharmacological properties of the leaves, a part of the plant not emphasized in traditional use.[15] This research led to the development of a highly concentrated and standardized leaf extract, designated EGb 761, which was designed to isolate beneficial compounds while removing potentially harmful ones. This marked a pivotal shift, moving the focus from the traditional use of seeds to the modern, scientific application of a purified leaf extract for cerebrovascular and peripheral circulatory disorders.[14] Today, Ginkgo Biloba Leaf Extract (GBE) is one of the best-selling herbal supplements in the world, particularly in Europe and the United States.[15]

C. Distinction Between Traditional (Seed) and Modern (Leaf Extract) Applications

A critical point of understanding, often obscured in popular marketing, is the fundamental divergence between the historical, traditional use of Ginkgo biloba and its contemporary application as a phytopharmaceutical supplement. This is not merely an evolution of use but a complete paradigm shift concerning the part of the plant utilized, the chemical constituents of interest, the method of preparation, and the primary therapeutic indications.

The historical basis of ginkgo in TCM is rooted almost entirely in the use of the seed, or "nut".[14] These were typically roasted and consumed to treat conditions primarily related to the lungs (asthma, bronchitis) and kidneys.[16] The modern Western application, in stark contrast, focuses exclusively on a highly processed and standardized extract derived from the leaves (GBE).[14] The development of GBE was not an attempt to replicate a traditional remedy but was a 20th-century pharmaceutical endeavor based on scientific investigation into the vasoregulatory properties of compounds found in the leaves.[19] Therefore, the widespread marketing of GBE as an "ancient remedy" for memory is misleading; the product sold today is a modern invention, not a direct descendant of the traditional use of the seeds for respiratory ailments.

This distinction is most crucial when considering safety. Raw or improperly prepared ginkgo seeds are toxic and dangerous.[21] They contain significant levels of 4’-O-methylpyridoxine, a neurotoxin commonly known as ginkgotoxin.[10] Ginkgotoxin is an anti-vitamin B6 compound that can interfere with the synthesis of the neurotransmitter GABA, leading to neurological symptoms, convulsions, loss of consciousness, and in severe cases, death.[21] Children are particularly vulnerable, and consuming as few as 10 roasted seeds can cause serious poisoning.[21] In contrast, high-quality, standardized leaf extracts are processed to remove harmful compounds and are generally considered safe for short-term oral use in adults, with a distinct and far more favorable safety profile.[1] This fundamental difference in chemistry and safety underscores that knowledge regarding the traditional use of ginkgo seeds cannot be extrapolated to the modern use of GBE, and vice versa.

II. Phytochemical Composition of Ginkgo Biloba Leaf Extracts

A. Primary Bioactive Constituents: Flavonoid Glycosides and Terpene Trilactones

The complex phytochemistry of Ginkgo biloba leaves includes over 60 bioactive ingredients, but the pharmacological effects attributed to GBE are primarily driven by two distinct classes of compounds: flavonoid glycosides and terpene trilactones.[13] The synergistic or additive effects of these compounds are believed to be responsible for the extract's multi-target mechanism of action.

Flavonoid Glycosides: This group of polyphenolic compounds typically constitutes 22-27% of a standardized ginkgo leaf extract.[15] They are primarily present as glycosides (attached to a sugar molecule) of the flavonols quercetin, kaempferol, and isorhamnetin.[20] Over 30 different flavonoids have been identified in ginkgo leaves, including flavones, biflavones, and catechins.[29] This class of compounds is largely credited with GBE's potent antioxidant and free-radical scavenging properties.[18] By neutralizing reactive oxygen species (ROS), these flavonoids help protect cellular structures, particularly lipids and proteins, from oxidative damage, a key mechanism in aging and neurodegenerative disease.[23] Their concentration increases as the leaves develop, reaching a maximum in summer leaves.[28]

Terpene Trilactones (Terpenoids): This is a unique class of molecules with complex cage-like structures that are exclusive to the Ginkgo biloba tree.[25] They are highly valued for their medicinal benefits, including neuroprotection and enhancement of memory and learning.[27] This fraction makes up approximately 5-7% of a standardized extract and is composed of two main subgroups [15]:

1. Ginkgolides: These are diterpenes with a distinctive 20-carbon cage structure. The major ginkgolides identified are A, B, C, J, and M.[20] Of these, Ginkgolide B is the most pharmacologically studied, recognized as a potent and highly specific antagonist of Platelet-Activating Factor (PAF).[13] PAF is a pro-inflammatory mediator involved in platelet aggregation, blood vessel permeability, and bronchoconstriction. By blocking the PAF receptor, ginkgolide B contributes significantly to GBE's effects on blood circulation and its anti-inflammatory properties.
2. Bilobalide: This is a sesquiterpene and is the most abundant single component within the terpene lactone fraction.[25] Bilobalide is known primarily for its neuroprotective activities, including protecting neurons from ischemic damage and mitochondrial dysfunction.[13]

The absolute bioavailability of these terpene lactones after oral administration is high, with studies showing values of 80% for ginkgolide A, 88% for ginkgolide B, and 79% for bilobalide.[20]

B. The Gold Standard: Profile of the Standardized Extract EGb 761

The vast majority of credible and influential clinical research on GBE has not been conducted on generic "ginkgo" but on a specific, proprietary, and highly purified pharmaceutical-grade product known as EGb 761.[20] Developed in the 1960s by Dr. Willmar Schwabe Pharmaceuticals in Germany, EGb 761 is marketed under brand names such as Tebonin®, Tanakan®, and Rökan®.[34] It is crucial to recognize that the scientific dossier supporting ginkgo's use is almost exclusively a dossier for EGb 761.

The manufacturing of EGb 761 involves a multi-step extraction and purification process designed to concentrate the desired active compounds while minimizing or removing undesirable ones. The process begins with dried leaves, often sourced from plantations in France, China, and the United States, and uses 60% aqueous acetone as the extraction solvent.[3] The resulting extract is then subjected to a series of purification steps to achieve a precise and consistent phytochemical profile.

This rigorous standardization is the defining characteristic of EGb 761 and is what distinguishes it from many over-the-counter dietary supplements. The composition of other ginkgo products can vary widely depending on the source of the leaves, the extraction method, and the quality control processes employed, which can lead to significant differences in both efficacy and safety.[22] The clinical findings from studies using EGb 761 cannot be reliably extrapolated to other, non-equivalent ginkgo extracts. This distinction is paramount for evidence-based clinical decision-making and explains why regulatory bodies like the European Medicines Agency specify the exact extraction method and solvent in their official monographs.[39] The precise and consistent chemical fingerprint of EGb 761 is detailed in Table 1.

Table 1: Phytochemical Composition of Standardized Ginkgo Biloba Extract (EGb 761)

Constituent Class	Sub-component(s)	Standardized Content (% of total extract)	Primary Associated Action	Source(s)
Flavonoid Glycosides	Quercetin, Kaempferol, Isorhamnetin (as glycosides)	22.0% – 27.0%	Antioxidant, Free-radical scavenging	20
Terpene Trilactones		5.0% – 7.0%	Neuroprotection, PAF Antagonism	20
	Ginkgolides	2.8% – 3.4%	PAF Antagonism (especially Ginkgolide B)	20
	Bilobalide	2.6% – 3.2%	Neuroprotection, Anti-ischemic effects	20
Ginkgolic Acids	Alkylphenols	< 5 ppm ($<0.0005\%$)	Allergenic, Potentially toxic/carcinogenic	27

C. Other Constituents and Potential Contaminants

Beyond the two primary classes of active compounds, GBE contains a variety of other substances, including proanthocyanidins, biflavones (e.g., ginkgetin, bilobetin), and a range of organic acids, which may contribute minorly to its overall biological activity.[15]

Of greater clinical significance are the potential contaminants and undesirable natural components that must be controlled during manufacturing. The most important of these are the ginkgolic acids. These are alkylphenolic compounds naturally present in the ginkgo leaf that are structurally similar to the allergens found in poison ivy.[15] They are known to be cytotoxic, allergenic, mutagenic, and potentially carcinogenic.[15] A key step in the production of high-quality extracts like EGb 761 is the reduction of ginkgolic acid content to a maximum level of 5 parts per million (ppm), a standard set to ensure the safety of the final product.[27] Many less-regulated dietary supplements may not adhere to this standard and could contain significantly higher levels of these harmful compounds.

Another toxicological concern is the potential for contamination with ginkgotoxin (4'-O-methylpyridoxine). While this neurotoxin is found predominantly in ginkgo seeds, poor manufacturing practices or adulteration could theoretically lead to its presence in leaf extracts.[10] As ginkgotoxin can induce seizures, its absence is a critical quality parameter for any GBE product, especially for individuals with a history of epilepsy.[42] The variability in the content of both active and toxic constituents across different commercial products underscores the difficulty in generalizing clinical trial results and highlights the importance of using well-characterized, standardized extracts in both research and clinical practice.

III. Pharmacological Profile: A Multi-Target Mechanism of Action

The therapeutic interest in Ginkgo biloba leaf extract stems from its complex and multifaceted pharmacological profile. Preclinical research has revealed that GBE does not operate through a single, targeted mechanism but rather as a pleiotropic agent, influencing multiple interconnected physiological and pathological pathways simultaneously. This "multi-target" activity provides a strong theoretical basis for its potential use in complex, multifactorial conditions such as neurodegenerative and vascular diseases. The primary mechanisms can be broadly categorized into vasoregulatory effects, neuroprotective and antioxidant actions, and modulation of neurotransmitter systems.

A. Vasoregulatory and Hemorheological Effects: Modulation of Blood Flow and Platelet Function

One of the earliest and most consistently studied properties of GBE is its ability to improve blood circulation.[18] This effect is not limited to a single vascular bed but has been observed in both the cerebral microcirculation and the peripheral vasculature, forming the basis for its use in conditions ranging from dementia to intermittent claudication.[43]

The primary mechanism underlying this effect is vasodilation, the relaxation and widening of blood vessels. GBE appears to promote this by enhancing the synthesis and release of endogenous vasodilators, most notably nitric oxide (NO) from the vascular endothelium.[18] By stimulating endothelium-derived relaxing factors, GBE helps to reduce vascular resistance and increase tissue perfusion.[20] This is particularly relevant in conditions of ischemia or inflammation, where GBE can moderate NO production and exert vasorelaxant properties.[24]

A second, highly specific mechanism involves the antagonism of Platelet-Activating Factor (PAF). The terpene lactone components of GBE, particularly ginkgolide B, are potent and specific inhibitors of the PAF receptor.[13] PAF is a powerful lipid mediator that promotes inflammation, increases vascular permeability, and is a strong inducer of platelet aggregation. By blocking PAF's action, GBE reduces the tendency of platelets to clump together, decreases blood viscosity, and inhibits the formation of microthrombi that can impede blood flow in small vessels.[15] This antiplatelet effect is a cornerstone of GBE's hemorheological activity but also forms the mechanistic basis for the primary safety concern associated with its use: an increased risk of bleeding.[21] Additionally, some in-vitro evidence suggests that GBE may possess fibrinolytic (clot-dissolving) properties, further contributing to its profile as an agent that improves blood fluidity.[20]

B. Neuroprotective and Antioxidant Mechanisms: Combating Oxidative Stress and Apoptosis

A central pillar of GBE's pharmacological activity is its potent neuroprotective effect, which is largely attributed to its antioxidant and anti-inflammatory properties. Oxidative stress—an imbalance between the production of damaging reactive oxygen species (ROS) and the body's ability to neutralize them—is a key pathological process in aging and in the development of neurodegenerative diseases like Alzheimer's.[30]

The flavonoid glycosides in GBE are powerful antioxidants that act as free radical scavengers.[15] They can directly neutralize a variety of ROS, including superoxide, hydroxyl, and peroxyl radicals, thereby protecting vital cellular components like DNA, proteins, and lipids from oxidative damage.[23] Beyond this direct scavenging effect, GBE has also been shown to indirectly bolster the body's defenses by increasing the expression and activity of endogenous antioxidant enzymes such as superoxide dismutase and catalase.[15]

This antioxidant activity is closely linked to the protection of mitochondria, the energy-producing powerhouses of the cell. Mitochondria are both a major source of ROS and highly vulnerable to their damaging effects. Mitochondrial dysfunction is a critical early event in neuronal cell death. GBE has been demonstrated to protect mitochondria from oxidative damage, stabilize their function, improve cellular energy metabolism (ATP production), and consequently inhibit the activation of apoptotic (programmed cell death) pathways.[49] By preserving mitochondrial integrity, GBE helps maintain neuronal health and resilience.

Furthermore, GBE exhibits anti-inflammatory effects. Chronic neuroinflammation contributes to the progression of neurodegenerative diseases. GBE has been shown to reduce markers of inflammation by modulating key signaling pathways, such as inhibiting the nuclear factor kappa B (NF-κB) pathway, and by decreasing the production of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and various interleukins (e.g., IL-1β, IL-6).[15]

C. Influence on Neurotransmitter Systems: Modulation of Dopamine, Serotonin, and Norepinephrine Pathways

In addition to its vascular and cellular protective effects, GBE also directly modulates neurotransmitter systems that are crucial for mood, attention, and cognitive function. This neuromodulatory action provides another mechanistic rationale for its use in cognitive and psychiatric disorders.

The most well-documented effect is on the dopaminergic system. Animal studies have consistently shown that chronic administration of EGb 761 increases the extracellular concentration of dopamine, particularly in the prefrontal cortex—a brain region critical for executive functions, working memory, and attention.[54] This effect is not due to a direct action on dopamine transporters (DAT) but is believed to result from a mild inhibition of the norepinephrine transporter (NET).[54] In the prefrontal cortex, NET is also responsible for the reuptake and clearance of dopamine. By partially inhibiting NET, GBE slows dopamine clearance, leading to its increased availability in the synapse.[54] Further evidence suggests GBE can also up-regulate the expression of key genes involved in dopamine synthesis and function, such as tyrosine hydroxylase and the transcription factor Nurr1, indicating a deeper, regulatory role in maintaining dopaminergic neuron health.[57]

GBE also influences the serotonergic and noradrenergic systems. In-vitro studies have demonstrated that GBE can inhibit the synaptic reuptake of both serotonin and norepinephrine.[20] It also appears to act as a reversible inhibitor of monoamine oxidase (MAO), the enzyme responsible for breaking down these neurotransmitters in the brain.[20] The combined effect of reuptake inhibition and MAO inhibition would theoretically lead to increased synaptic levels of serotonin and norepinephrine, which could contribute to potential antidepressant and anxiolytic effects.

Finally, some evidence points to a modest effect on the cholinergic system. GBE has been reported to exhibit mild anticholinesterase activity, which would inhibit the breakdown of acetylcholine and enhance cholinergic transmission.[20] This mechanism is shared by several first-line pharmaceutical treatments for Alzheimer's disease, such as donepezil.

The interplay of these diverse mechanisms—improving blood flow, reducing oxidative stress, protecting mitochondria, and modulating key neurotransmitter systems—illustrates the pleiotropic nature of GBE. This multi-target profile is theoretically advantageous for treating complex, multifactorial diseases like dementia, where vascular compromise, inflammation, oxidative damage, and neurotransmitter imbalances all contribute to the pathology. However, this same complexity presents a challenge. The effects on any single pathway may be subtle, and this diffusion of action across multiple targets may explain why the robust and promising results seen in preclinical models do not always translate into clinically significant and consistent benefits in large-scale human trials.

IV. Clinical Efficacy and Therapeutic Applications: An Evidence-Based Review

The transition from promising preclinical pharmacology to definitive clinical benefit has been a complex and often contentious journey for Ginkgo biloba leaf extract. Decades of research have produced a large but highly heterogeneous body of evidence, leading to conflicting conclusions among researchers, clinicians, and regulatory bodies. A critical evaluation reveals that the efficacy of GBE is highly dependent on several key factors: the specific clinical indication being addressed (e.g., treatment vs. prevention), the severity of the underlying condition, the specific formulation of the extract used, the daily dosage, and the duration of treatment.

A. Neurocognitive and Psychiatric Conditions

1. Dementia (Alzheimer's, Vascular, Mixed): A Critical Analysis of Contradictory Evidence

The primary focus of GBE research has been its potential role in the treatment and prevention of dementia. The evidence in this area is the most extensive but also the most polarized. A careful analysis of the highest-quality studies reveals a clear pattern: GBE has consistently failed as a preventative agent but shows a modest, yet statistically significant, signal as a symptomatic treatment for existing mild to moderate dementia.

Evidence Against Efficacy in Prevention: The most definitive evidence regarding dementia prevention comes from two large, long-term, well-designed randomized controlled trials (RCTs). The Ginkgo Evaluation of Memory (GEM) Study, which enrolled over 3,000 elderly individuals with normal cognition or mild cognitive impairment (MCI), found that a dose of 120 mg of EGb 761 twice daily (240 mg/day) was not effective in reducing the overall incidence of all-cause dementia or Alzheimer's disease over a median follow-up of 6.1 years.[24] Similarly, the French GuidAge trial, which followed over 2,800 participants for five years, also found that 240 mg/day of EGb 761 did not reduce the risk of progression to Alzheimer's disease compared to placebo.[24] These high-quality trials provide strong evidence that GBE should not be recommended for the primary prevention of dementia.

Evidence for Efficacy in Treatment: In contrast to the prevention data, a substantial body of evidence supports a modest therapeutic benefit for patients already diagnosed with mild to moderate dementia. Multiple systematic reviews and meta-analyses, primarily focusing on the standardized extract EGb 761 at a dose of 240 mg/day, have concluded that GBE is superior to placebo in stabilizing or slowing the decline across three key domains: cognition, activities of daily living (ADLs), and global clinical assessment.[9] These benefits typically become apparent after a treatment duration of at least 22-26 weeks.[63] The effect size is generally considered modest but is comparable to that seen with approved acetylcholinesterase inhibitors for mild dementia.[9] The benefit appears to be most pronounced in dementia patients who also present with significant neuropsychiatric symptoms (NPS), such as anxiety, apathy, and depression.[37]

It is important to acknowledge that the evidence is not monolithic. The Cochrane Collaboration has historically concluded that the evidence is inconsistent and unreliable, citing methodological weaknesses in many of the included trials.[53] However, more recent meta-analyses incorporating newer, higher-quality studies have tended to find a more consistent positive signal for the 240 mg/day dose of EGb 761.[37] This discrepancy highlights the evolution of the evidence base and the importance of focusing on well-conducted trials using a specific, standardized product and adequate dosage. The key findings from the most influential trials and reviews are summarized in Table 2.

Table 2: Summary of Meta-Analyses and Major RCTs on GBE for Dementia/Cognitive Decline

Study / Review	Patient Population	GBE Dosage & Formulation	Duration	Key Findings	Authors' Conclusion	Source(s)
GEM Study (DeKosky et al., 2008)	>3,000 elderly (≥75 years) with normal cognition or MCI	120 mg BID (240 mg/day) EGb 761	~6.1 years	No difference in incidence of all-cause dementia or Alzheimer's disease vs. placebo.	GBE was not effective in reducing the incidence of dementia.	24
GuidAge Study (Vellas et al., 2012)	>2,800 elderly (≥70 years) with memory complaints	120 mg BID (240 mg/day) EGb 761	5 years	No significant difference in the risk of progression to Alzheimer's disease vs. placebo.	Long-term use of GBE did not reduce the risk of progressing to Alzheimer's disease.	24
Tan et al. (2015) Meta-Analysis	9 RCTs; Patients with cognitive impairment and dementia	Primarily 240 mg/day EGb 761	22-26 weeks	Statistically significant superiority of GBE over placebo for cognition, ADLs, and global change. Benefit was greatest in patients with NPS.	EGb 761 at 240 mg/day is able to stabilize or slow decline in cognitive impairment and dementia.	63
Gauthier & Schlaefke (2014) Meta-Analysis	7 RCTs; Patients with dementia (AD, VaD, or mixed)	120 mg or 240 mg/day EGb 761	22-26 weeks	Statistically significant superiority of GBE over placebo for cognition, ADLs, and global rating. Responder analyses also favored GBE.	Confirmed the efficacy and good tolerability of EGb 761 in patients with dementia.	37
Cochrane Review (Birks et al., 2009 update)	36 trials; Cognitive impairment or dementia	Varied	Varied	Evidence is inconsistent and unreliable. No convincing evidence that GBE is effective for dementia or cognitive impairment.	Evidence for GBE is inconsistent and unreliable.	53

2. Mild Cognitive Impairment (MCI) and Age-Related Cognitive Decline

For individuals with Mild Cognitive Impairment (MCI), a symptomatic stage that can precede dementia, the evidence for GBE is mixed but leans slightly positive for symptomatic treatment. Some systematic reviews suggest that GBE may improve memory and modestly slow cognitive decline in patients who already have a diagnosed impairment, particularly when neuropsychiatric symptoms are present.[53] However, as established by the GEM and GuidAge trials, it does not prevent the progression from MCI to dementia.[24]

For healthy adults experiencing normal, age-related cognitive changes, the evidence is largely negative. Despite its popular reputation as a "memory booster" or "smart drug," the majority of well-controlled studies show that GBE does not produce measurable improvements in memory, attention, or executive function in cognitively healthy individuals.[18] While a few small, older studies suggested slight improvements in certain cognitive domains, these findings have not been consistently replicated in larger, more rigorous trials.[23]

3. Anxiety, Depression, and Schizophrenia: Review of Evidence for Adjunctive Use

GBE has been investigated as a complementary therapy for several psychiatric disorders, often with the goal of augmenting conventional treatments or mitigating their side effects.

• Anxiety: There is some evidence to suggest a modest anxiolytic effect. One clinical trial found that EGb 761, at doses of 240 mg and 480 mg per day, significantly reduced symptoms of Generalized Anxiety Disorder (GAD) and Adjustment Disorder with Anxious Mood compared to placebo over a 4-week period.[21] However, the effect is considered small, and the overall body of evidence is not yet conclusive enough to recommend it as a standalone treatment.[72]
• Schizophrenia: GBE has shown some promise as an adjunctive therapy. When added to conventional antipsychotic medications, GBE may help reduce negative symptoms of schizophrenia (e.g., apathy, social withdrawal) and may also alleviate certain medication-induced side effects, most notably tardive dyskinesia, a movement disorder.[9]
• Depression: The evidence for GBE in depression is limited to its use as an add-on treatment. A small RCT suggested that EGb 761, when used in conjunction with the antidepressant citalopram, could lead to greater improvements in depressive symptoms and cognitive function than citalopram alone.[24] A recent meta-analysis also supported the idea that GBE might reduce depressive symptoms.[74]

B. Vascular and Neurosensory Disorders

1. Intermittent Claudication

Intermittent claudication, characterized by ischemic muscle pain in the legs during exercise, is a hallmark symptom of peripheral artery disease (PAD). Given GBE's known effects on blood flow, it has been extensively studied for this condition. Despite this, the clinical results have been disappointing. Multiple systematic reviews, including several by the Cochrane Collaboration, have consistently concluded that GBE provides no clinically significant benefit for patients with intermittent claudication.[23] While some meta-analyses detected a small, statistically borderline increase in pain-free walking distance (on the order of 34-64 meters), this improvement is not considered clinically meaningful and is likely inflated by publication bias.[76]

2. Tinnitus and Vertigo

• Tinnitus: GBE is one of the most widely used and marketed supplements for tinnitus (ringing in the ears). However, the scientific evidence overwhelmingly refutes its efficacy. A series of high-quality systematic reviews from the Cochrane Collaboration and others have unequivocally concluded that GBE is not effective for treating tinnitus when it is the primary complaint.[82] The perceived benefits reported by some users are largely attributed to a strong placebo effect, which is common in tinnitus treatment studies.[82]
• Vertigo: In contrast to tinnitus, there is some positive evidence for GBE in treating vertigo (dizziness). Studies suggest that GBE can improve symptoms of dizziness, particularly when they are caused by underlying balance disorders or have a vascular origin.[21] A three-month RCT demonstrated that EGb 761 was significantly more effective than placebo in reducing the intensity, frequency, and duration of vertiginous syndrome.[24]

3. Stroke Rehabilitation

There is emerging evidence that GBE may play a beneficial role as an adjunctive therapy in the rehabilitation of patients who have had an ischemic stroke. Several studies have found that GBE, when taken alongside standard post-stroke therapy, appears to improve cognitive function, memory, and the ability to perform activities of daily living compared to standard therapy alone.[21] While promising, this area requires further research with larger, more robust trials to confirm these benefits.

V. Comprehensive Safety, Tolerability, and Toxicological Profile

The safety of Ginkgo biloba leaf extract is a complex topic marked by a significant divergence between data from controlled clinical trials and observations from post-marketing surveillance and case reports. While standardized extracts are generally well-tolerated in trial settings, real-world use has been associated with several serious safety concerns, necessitating careful patient counseling and risk assessment.

A. Common and Minor Adverse Effects

In the context of randomized controlled trials, standardized GBE, particularly EGb 761, has demonstrated a favorable safety profile. The incidence of adverse events in groups receiving GBE is often statistically indistinguishable from that of placebo groups.[67] When side effects do occur, they are typically mild and transient. The most commonly reported minor adverse events include:

• Gastrointestinal symptoms: Nausea, stomach upset, diarrhea, and constipation.[23]
• Neurological symptoms: Headache and dizziness.[1]
• Cardiovascular symptoms: Heart palpitations (a feeling of a pounding or racing heart).[23]
• Dermatological symptoms: Allergic skin reactions or rashes.[21]

B. Significant Safety Concerns

Beyond minor side effects, three major safety concerns have been raised regarding GBE: bleeding risk, seizurogenic potential, and long-term carcinogenicity.

1. Bleeding Risk: This is the most prominent and clinically relevant safety issue. The antiplatelet activity of GBE, mediated through PAF antagonism, provides a plausible biological mechanism for an increased risk of bleeding.[1] This theoretical risk is substantiated by a substantial number of published case reports linking GBE use to spontaneous bleeding events. These reports include serious and life-threatening episodes such as subdural hematomas, intracerebral hemorrhage, and spontaneous hyphema (bleeding into the eye).[38] Many of these cases occurred in patients concurrently using other medications that affect coagulation, such as aspirin or warfarin, suggesting an additive effect.[93] This real-world signal from case reports creates a significant evidence conflict. The highest level of evidence—large-scale RCTs and meta-analyses of standardized EGb 761—has consistently failed to find a statistically significant increase in the rate of major bleeding events compared to placebo.[90] This paradox suggests that while the intrinsic risk of a highly purified, standardized product in a carefully selected and monitored trial population may be low, the risk in the general population is likely amplified. Factors such as the use of non-standardized supplements of variable quality, widespread polypharmacy (especially with over-the-counter NSAIDs), and underlying patient vulnerabilities (e.g., undiagnosed bleeding tendencies) likely contribute to the manifestation of these bleeding events in the real world. Given the severity of the potential harm, clinical guidance must remain conservative and prioritize the warnings derived from post-marketing surveillance.
2. Seizurogenic Potential: GBE may lower the seizure threshold, potentially increasing the risk of seizures.[21] This risk is thought to be primarily associated with the neurotoxin ginkgotoxin (4'-O-methylpyridoxine), which is concentrated in the seeds but can be a contaminant in poorly manufactured leaf extracts.[42] Individuals with a pre-existing diagnosis of epilepsy or a history of seizures are at the highest risk and should avoid GBE.[21] The risk may also be elevated when GBE is taken with other medications that can lower the seizure threshold.[23]
3. Carcinogenicity Data: Long-term safety has been called into question by a 2-year bioassay conducted by the U.S. National Toxicology Program (NTP). In this study, rodents were administered a specific GBE via gavage. The results found "clear evidence of carcinogenic activity" in mice, based on an increased incidence of hepatocellular carcinoma and hepatoblastoma (liver cancers), and "some evidence of carcinogenic activity" in rats, based on an increased incidence of thyroid cancer.[22] Based on these animal data, the International Agency for Research on Cancer (IARC) has classified GBE as a "possible human carcinogen (Group 2B)".[22] The applicability of these findings to human consumption of standardized extracts like EGb 761 is a subject of intense debate. Proponents of GBE argue that the extract used in the NTP study was not representative of the high-quality products used in major clinical trials and that the high doses administered to rodents are not comparable to human therapeutic doses.[100] Nevertheless, this finding remains a significant point of concern for long-term use.

C. Contraindications and Specific Warnings

Based on the known pharmacological effects and safety concerns, GBE is contraindicated or should be used with extreme caution in several specific populations:

• Pregnancy and Lactation: GBE is considered possibly unsafe during pregnancy. Its antiplatelet effects may increase the risk of excessive bleeding during labor and delivery, and there is a theoretical risk it could induce premature labor.[1] The safety of GBE during breastfeeding has not been established, and its use should be avoided.[1]
• Bleeding Disorders: Individuals with hemophilia or other congenital or acquired bleeding disorders should not use GBE due to the increased risk of spontaneous bleeding.[21]
• Planned Surgery: Due to the risk of increased intraoperative and postoperative bleeding, it is universally recommended that patients discontinue GBE use at least two weeks before any scheduled surgical or dental procedure.[21]
• Epilepsy or Seizure History: Individuals with a history of seizures should avoid GBE due to its potential to lower the seizure threshold and provoke seizure activity.[21]
• Diabetes: GBE may interfere with blood glucose regulation. Patients with diabetes who choose to use GBE must monitor their blood sugar levels closely, as adjustments to their diabetes medications may be necessary.[21]

VI. Clinically Significant Drug Interactions

The potential for drug interactions is a major clinical consideration with GBE, particularly given its use by an older population often subject to polypharmacy. Interactions can be pharmacodynamic (where GBE's effects on the body add to or oppose those of another drug) or pharmacokinetic (where GBE affects the absorption, metabolism, or excretion of another drug).

A. Pharmacodynamic Interactions: Increased Bleeding Risk

The most critical and well-documented class of interactions involves GBE's pharmacodynamic effect on hemostasis. As established, GBE inhibits platelet aggregation, primarily through PAF antagonism.[46] When co-administered with other medications that thin the blood or inhibit platelet function, the risk of bleeding can be significantly amplified. This additive or synergistic effect is the basis for the most serious warnings associated with GBE use. Clinicians must exercise extreme caution when a patient is taking GBE concurrently with any of the following:

• Anticoagulant Medications: These drugs, such as warfarin (Coumadin) and direct oral anticoagulants (DOACs) like apixaban (Eliquis) and rivaroxaban, slow the blood clotting cascade. Combining them with GBE's antiplatelet effect creates a dual-front assault on hemostasis, increasing the risk of major bleeding.[21] A large retrospective analysis of veterans found that concurrent use of ginkgo and warfarin was associated with a significantly increased hazard ratio for bleeding events.[106]
• Antiplatelet Medications: Drugs like aspirin and clopidogrel (Plavix) also inhibit platelet function. Co-administration with GBE can potentiate this effect, raising the risk of bruising and hemorrhage.[42] Retrospective data show that interactions with aspirin and clopidogrel are among the most frequently observed with GBE.[108]
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Common over-the-counter drugs like ibuprofen (Advil, Motrin) and naproxen also have antiplatelet effects. The combination of GBE and NSAIDs can increase the risk of bleeding, particularly gastrointestinal bleeding.[21] Case reports have linked the combination of GBE and ibuprofen to fatal intracerebral hemorrhage.[113]

While some controlled clinical trials using the standardized extract EGb 761 have not shown a significant interaction with warfarin or aspirin, the weight of real-world evidence from case reports and observational studies necessitates a highly cautious approach.[90]

B. Pharmacokinetic and Other Interactions

GBE can also interact with medications through other mechanisms, including altering drug metabolism or acting on the central nervous system.

• Anticonvulsants: GBE may reduce the efficacy of medications used to prevent seizures (e.g., carbamazepine, valproic acid). The proposed mechanism is twofold: GBE itself may lower the seizure threshold, and it may also induce metabolic enzymes that accelerate the clearance of anticonvulsant drugs, lowering their plasma concentrations and therapeutic effect.[23]
• Antidepressants: The interaction with antidepressants is complex.
• Efficacy: GBE may decrease the effectiveness of certain selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (Prozac).[23]
• Serotonin Syndrome: Due to its potential MAO-inhibiting properties, there is a theoretical risk that combining GBE with SSRIs or other serotonergic drugs could precipitate serotonin syndrome, a potentially life-threatening condition of excessive serotonin activity. While this is poorly researched in humans, animal studies support the possibility.[98]
• Bleeding Risk: As many SSRIs also have mild antiplatelet effects, combining them with GBE may further increase the risk of bleeding complications, which was the most common interaction seen in a review of case reports.[115]
• Diabetes Medications: GBE has been reported to alter blood glucose levels, although the direction of the effect is inconsistent across studies. This can interfere with the management of diabetes, potentially reducing the efficacy of oral hypoglycemics or insulin. Patients with diabetes taking GBE require close monitoring of their blood sugar.[21]
• Alprazolam (Xanax): Evidence suggests that GBE may increase the metabolic clearance of alprazolam, thereby reducing its plasma concentration and clinical effectiveness as an anxiolytic.[23]
• Cytochrome P450 (CYP) Enzymes: GBE and its constituents have been shown in in-vitro studies to inhibit or induce various CYP450 enzymes (e.g., CYP3A4, CYP2C19, CYP2C9), which are responsible for metabolizing a vast number of prescription drugs.[21] This creates a high potential for pharmacokinetic interactions. However, clinical studies in humans using the standardized extract EGb 761 at recommended doses (≤240 mg/day) have generally failed to show clinically significant effects on these enzymes.[117] This suggests that the risk of pharmacokinetic interactions may be low with high-quality, standardized extracts at therapeutic doses, but could be significant with higher doses or with poorly characterized supplements.

The most clinically relevant interactions are summarized for quick reference in Table 3.

Table 3: Clinically Significant Drug Interactions with Ginkgo Biloba Leaf Extract

Drug / Drug Class	Potential Interaction / Effect	Proposed Mechanism	Clinical Recommendation / Severity	Source(s)
Anticoagulants (e.g., Warfarin)	Increased risk of major bleeding, hemorrhage.	Pharmacodynamic: Additive antiplatelet effect with anticoagulant effect.	Generally Avoid. High risk of serious bleeding.	23
Antiplatelet Drugs (e.g., Aspirin, Clopidogrel)	Increased risk of bleeding.	Pharmacodynamic: Additive inhibition of platelet aggregation.	Generally Avoid. High risk of bleeding.	108
NSAIDs (e.g., Ibuprofen, Naproxen)	Increased risk of bleeding, especially GI bleeding.	Pharmacodynamic: Additive inhibition of platelet aggregation.	Use with Extreme Caution or Avoid.	23
Anticonvulsants (e.g., Carbamazepine, Valproic Acid)	Reduced efficacy of anticonvulsant; increased seizure risk.	Pharmacodynamic (lowers seizure threshold) & Pharmacokinetic (potential enzyme induction).	Avoid. May precipitate seizures.	23
Antidepressants (SSRIs) (e.g., Fluoxetine, Sertraline)	Reduced efficacy of SSRI; potential risk of serotonin syndrome; increased bleeding risk.	Pharmacokinetic (reduced efficacy) & Pharmacodynamic (serotonin syndrome, antiplatelet effects).	Use with Caution. Monitor for efficacy and adverse effects.	23
Alprazolam (Xanax)	Reduced efficacy of alprazolam.	Pharmacokinetic: Increased metabolic clearance of alprazolam.	Use with Caution. Monitor for reduced anxiolytic effect.	23
Diabetes Medications (e.g., Metformin, Insulin)	Altered blood glucose control.	Pharmacodynamic: GBE may affect blood sugar levels.	Use with Caution. Requires close blood glucose monitoring.	21
Certain Statins (e.g., Atorvastatin, Simvastatin)	Reduced efficacy of statins.	Pharmacokinetic: Altered metabolism of statins.	Use with Caution.	23

VII. Formulations, Dosage, and Global Regulatory Landscape

The clinical application and safety of Ginkgo biloba leaf extract are intrinsically linked to its formulation, dosage, and the regulatory framework under which it is marketed. Significant variations in these areas across the globe contribute to the confusion and controversy surrounding its use.

A. Common Formulations and the Importance of Standardization

GBE is widely available to consumers in a variety of formulations, including tablets, capsules, liquid extracts, and dried leaves intended for making tea.[18] However, the most critical factor determining the potential efficacy and safety of a ginkgo product is not its form but its level of standardization.

As has been established, the vast majority of robust clinical data pertains to specific, proprietary extracts, most notably EGb 761, which are standardized to a consistent concentration of active ingredients: approximately 24% flavonoid glycosides and 6% terpene trilactones.[34] This process also crucially involves the removal of potentially harmful ginkgolic acids to below 5 ppm.[27] Many products sold as dietary supplements, especially in the United States, may not adhere to this level of rigorous standardization. The content of active compounds can vary significantly from what is stated on the label, and levels of contaminants may be higher. This lack of consistency means that the safety and efficacy demonstrated in trials of EGb 761 cannot be assumed for all commercial ginkgo products. Therefore, for any therapeutic consideration, the use of a product specifying standardization to the 24%/6% ratio is essential.[125]

B. Evidence-Based Dosage Recommendations

While there is no single universally approved dosage for GBE, a consensus has emerged from the body of clinical research regarding therapeutically effective dose ranges for specific conditions, almost always referring to standardized extracts.

• Dementia and Cognitive Impairment: For the symptomatic treatment of mild to moderate dementia, the most consistently effective dose identified in meta-analyses is 240 mg per day.[21] This is typically administered in two divided doses of 120 mg.[24] Studies using lower doses (e.g., less than 200 mg/day) have often failed to show a clinically relevant effect, suggesting a clear dose-dependency for this indication.[66]
• Intermittent Claudication: Clinical trials for this condition have generally used doses in the range of 120 mg to 240 mg per day, divided into two or three doses.[126]
• Anxiety: The limited clinical trial data for Generalized Anxiety Disorder used doses of 240 mg and 480 mg per day.[71]
• Other Conditions: Dosages reported in studies for other conditions vary widely, from 120-160 mg/day for vertigo to as high as 360 mg/day for Raynaud's disease.[126]

It is generally recommended not to exceed a total daily dose of 240 mg, as higher doses are associated with an increased risk of side effects and drug interactions without clear evidence of increased benefit.[127] For any indication, it may take 4-6 weeks of consistent use before any effects become noticeable.[130]

C. Comparative Global Regulatory Status

The legal status and regulation of GBE vary dramatically across different regions, reflecting fundamentally different philosophical approaches to herbal products. This regulatory dissonance is a major source of confusion for consumers, clinicians, and researchers, as the same substance can be a prescription medicine, a loosely regulated supplement, or an unapproved food additive depending on geographic location.

• United States (Food and Drug Administration - FDA): In the U.S., GBE is not approved as a drug for the prevention or treatment of any medical condition.[24] It is primarily sold as a dietary supplement under the framework of the Dietary Supplement Health and Education Act of 1994 (DSHEA). This means manufacturers can market GBE without providing the FDA with evidence of safety or efficacy prior to sale. The FDA's role is largely reactive, taking action only after a product is found to be unsafe or misbranded. Furthermore, the FDA has explicitly determined that GBE is not Generally Recognized As Safe (GRAS) for use as an ingredient in conventional foods, effectively making it an unapproved food additive.[100] This determination was based on safety concerns, including the carcinogenicity findings from the NTP animal studies.[100] The FDA has issued numerous warning letters to companies making illegal health claims about their ginkgo-containing products.[10]
• European Union (European Medicines Agency - EMA): The regulatory approach in Europe is markedly different. The EMA's Committee on Herbal Medicinal Products (HMPC) has established a European Union herbal monograph for Ginkgo folium, formally recognizing it as a medicinal product.[133] The monograph creates two distinct pathways:

1. "Well-Established Medicinal Use": This status is granted to specific, high-quality dry extracts (matching the profile of EGb 761) for the indication of "improvement of (age-associated) cognitive impairment and of quality of life in mild dementia".[39] This classification requires bibliographic data demonstrating at least 10 years of medicinal use within the EU, supported by robust scientific evidence of efficacy and safety.
2. "Traditional Herbal Medicinal Product": This status is granted to powdered leaf preparations for the relief of minor circulatory disorders (e.g., heavy legs, cold extremities).39 This pathway requires evidence of safe use for at least 30 years (15 within the EU) but does not require the same level of clinical efficacy data as the "well-established use" category. This dual-pathway system allows GBE to be regulated as a legitimate, evidence-based medicine for specific indications.

• Australia (Therapeutic Goods Administration - TGA): Australia employs a risk-based, two-tiered system for complementary medicines. GBE products are regulated as therapeutic goods and must be included on the Australian Register of Therapeutic Goods (ARTG).[134] The vast majority of the over 400 ginkgo products on the ARTG are "listed" medicines (AUST L).[136] This means the TGA has assessed them for quality and safety (i.e., good manufacturing practice) but not for efficacy. Manufacturers can make low-level health claims based on traditional use or scientific evidence that the TGA has not independently verified. A smaller number of higher-risk products may be "registered" medicines (AUST R), which requires the sponsor to submit a full dossier of evidence for TGA evaluation of safety, quality, and efficacy. Products containing the standardized extract EGb 761, such as Blackmores Tebonin®, are available in Australia as listed medicines.[138]

This global regulatory patchwork is summarized in Table 4.

Table 4: Comparative Global Regulatory Status of Ginkgo Biloba Leaf Extract

Region / Jurisdiction	Regulatory Body	Primary Classification	Key Regulatory Position / Implications	Source(s)
United States	Food and Drug Administration (FDA)	Dietary Supplement; Unapproved Food Additive	Not approved to treat any disease. Regulated post-market for safety. Not considered GRAS for use in food. Health claims are highly restricted.	24
European Union	European Medicines Agency (EMA)	Herbal Medicinal Product	Recognized as a medicine. "Well-established use" for specific extracts (e.g., EGb 761) in mild dementia. "Traditional use" for powdered leaf in minor circulatory issues.	39
Australia	Therapeutic Goods Administration (TGA)	Complementary Medicine (Mostly "Listed")	Regulated as a therapeutic good. Most products are "Listed" (AUST L), assessed for quality and safety, but not efficacy. Low-level health claims are permitted.	134

VIII. Synthesis and Concluding Expert Remarks

A. Summary of the Evidence: Reconciling Preclinical Promise with Clinical Realities

The scientific and clinical narrative of Ginkgo biloba leaf extract is one of profound complexity, characterized by a significant chasm between its robust preclinical pharmacological profile and its contested efficacy in human clinical trials. Preclinical data compellingly demonstrate that GBE is a multi-target agent, exerting beneficial effects through vasoregulatory, antioxidant, anti-inflammatory, mitochondrial-protective, and neuromodulatory mechanisms. This pleiotropic action provides a strong theoretical rationale for its application in complex, age-related disorders like dementia.

However, this preclinical promise has not translated into unequivocal clinical success. The body of evidence from human studies, while vast, is fraught with inconsistencies. A critical synthesis of the highest-quality data leads to several nuanced conclusions. First, GBE is not effective as a primary preventative agent for dementia or cognitive decline in healthy older adults. Large, well-conducted trials like the GEM study have definitively shown a lack of benefit in this context. Second, GBE is not a cognitive enhancer or "smart drug" for healthy young or middle-aged individuals; evidence for this popular application is weak and inconsistent. Third, for most of the other conditions for which it is commonly used, such as intermittent claudication and tinnitus, the weight of high-quality evidence indicates a lack of clinically significant efficacy.

The sole area where a consistent, albeit modest, therapeutic signal persists is in the symptomatic treatment of existing mild to moderate dementia. Meta-analyses of trials using a specific, high-quality standardized extract (EGb 761) at an adequate dose (240 mg/day) for a sufficient duration (≥ 6 months) consistently show a statistically significant, though small, advantage over placebo in slowing the decline of cognition, function, and global status. This benefit appears most pronounced in patients with comorbid neuropsychiatric symptoms.

B. Key Considerations for Clinical Practice and Patient Counseling

For healthcare professionals advising patients on the use of GBE, an evidence-based and cautious approach is paramount. The following points should guide clinical practice and counseling:

1. Emphasize Product Specificity: It is crucial to educate patients that the clinical evidence for "ginkgo" is almost exclusively for the standardized pharmaceutical-grade extract EGb 761. The safety and efficacy of other, less-regulated dietary supplements cannot be assumed and may be substantially different.
2. Manage Therapeutic Expectations: Patients should be counseled that GBE is not a cure for dementia nor a powerful memory-enhancing drug. For the appropriate patient (i.e., one with diagnosed mild dementia), it may offer a modest benefit in slowing symptomatic progression, but it will not reverse the disease or prevent its onset.
3. Prioritize Safety and Interaction Screening: The most critical role for the clinician is to ensure patient safety. A thorough history must be taken to screen for contraindications, including bleeding disorders, epilepsy, and pregnancy. A comprehensive medication review is mandatory to identify potential drug interactions, with particular attention paid to anticoagulants, antiplatelet agents (including aspirin and NSAIDs), and anticonvulsants.
4. Provide Clear Preoperative Guidance: All patients should be unequivocally advised to discontinue GBE use at least two weeks prior to any planned surgical or dental procedure to minimize the risk of excessive bleeding.

C. Future Research Directions

Despite decades of study, several key questions regarding GBE remain unanswered, warranting further investigation:

• Long-Term Safety: The carcinogenicity signal from the NTP rodent studies needs to be reconciled with human data. Long-term epidemiological studies could help clarify whether any real-world cancer risk exists for humans at therapeutic doses.
• Bleeding Risk Discrepancy: The stark contrast between the lack of a bleeding signal in RCTs and the persistent signal from case reports needs to be systematically investigated. Research into how product variability, genetic factors, and polypharmacy contribute to real-world bleeding events is needed.
• Adjunctive Psychiatric Use: The preliminary positive findings for GBE as an adjunctive treatment in schizophrenia and depression are intriguing. Larger, more robust RCTs are required to confirm these benefits and define its role in psychiatric care.
• Head-to-Head Trials: There is a lack of head-to-head trials comparing GBE to approved dementia medications or to other standardized ginkgo extracts. Such studies would be invaluable for positioning GBE within the therapeutic armamentarium.

In conclusion, Ginkgo biloba leaf extract, particularly the standardized formulation EGb 761, occupies a complex and contested space in modern medicine. It is not the panacea that marketing often suggests, but neither is it without a plausible biological basis and a narrow, evidence-supported therapeutic niche. Its future role will depend on continued rigorous research to clarify its long-term safety and definitively establish its clinical utility in specific patient populations.

Works cited

1. Ginkgo: Usefulness and Safety | NCCIH, accessed October 29, 2025, https://www.nccih.nih.gov/health/ginkgo
2. Ginkgo tree: Ginkgo biloba - University of Pretoria, accessed October 29, 2025, https://www.up.ac.za/botanical-garden/article/3108036/ginkgo-tree-ginkgo-biloba
3. Ginkgo biloba - Trees - Rowan University Arboretum, accessed October 29, 2025, https://arboretum.rowan.edu/trees-species/ginkgo-biloba/
4. a true “living fossil” The Ginkgo - Oregon.gov, accessed October 29, 2025, https://www.oregon.gov/odf/Documents/forestbenefits/Gingko.pdf
5. Ginkgo Biloba - UCR Botanic Gardens - University of California, Riverside, accessed October 29, 2025, https://gardens.ucr.edu/news/2023/01/20/ginkgo-biloba
6. How saving Ginkgo biloba could save humankind: Paleobotanical Future, accessed October 29, 2025, https://ethnobiology.org/forage/blog/how-saving-ginkgo-biloba-could-save-humankind-paleobotanical-future
7. Ginkgo Biloba | University College Cork, accessed October 29, 2025, https://www.ucc.ie/en/tree-explorers/trees/a-z/ginkgobiloba/
8. Oxford University Plants 400: Ginkgo biloba - BRAHMS: Oxford, accessed October 29, 2025, https://herbaria.plants.ox.ac.uk/bol/plants400/Profiles/GH/Ginkgo
9. A Systematic Review and Meta-Analysis of Ginkgo biloba in ... - NIH, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3679686/
10. Ginkgo biloba - Wikipedia, accessed October 29, 2025, https://en.wikipedia.org/wiki/Ginkgo_biloba
11. Ginkgo Biloba leaf extract - American Botanical Council, accessed October 29, 2025, https://www.herbalgram.org/resources/expanded-commission-e-monographs/ginkgo-biloba-leaf-extract/
12. en.wikipedia.org, accessed October 29, 2025, https://en.wikipedia.org/wiki/Ginkgo_biloba#:~:text=Ginkgo%20biloba%2C%20commonly%20known%20as,tree%20native%20to%20East%20Asia.
13. Ginkgo biloba L.: An Updated Review on the Pharmacological Activities, Pharmacokinetics and Drug Interactions Review - KnE Publishing, accessed October 29, 2025, https://publish.kne-publishing.com/index.php/tim/article/download/17478/16336
14. The Life Story of The Oldest Tree on Earth - Yale E360, accessed October 29, 2025, https://e360.yale.edu/features/peter_crane_history_of_ginkgo_earths_oldest_tree
15. The Potential of Ginkgo biloba as a Source of Biologically Active ..., accessed October 29, 2025, https://www.mdpi.com/1420-3049/28/10/3993
16. Validation of a 16th Century Traditional Chinese Medicine Use of Ginkgo biloba as a Topical Antimicrobial - Frontiers, accessed October 29, 2025, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.00775/full
17. Ginkgo biloba: A Treasure of Functional Phytochemicals with Multimedicinal Applications, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8901348/
18. Ginkgo biloba possible benefits and risks - Healthline, accessed October 29, 2025, https://www.healthline.com/nutrition/ginkgo-biloba-benefits
19. Ginkgo | Herbs - Herbal Reality, accessed October 29, 2025, https://www.herbalreality.com/herb/ginkgo/
20. Ginkgo biloba: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 29, 2025, https://go.drugbank.com/drugs/DB01381
21. Ginkgo: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews, accessed October 29, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-333/ginkgo
22. Review of Ginkgo biloba-induced toxicity, from experimental studies ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6373469/
23. Ginkgo - Mayo Clinic, accessed October 29, 2025, https://www.mayoclinic.org/drugs-supplements-ginkgo/art-20362032
24. Ginkgo Biloba - StatPearls - NCBI Bookshelf, accessed October 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK541024/
25. Bioactive terpenoids and flavonoids from ginkgo biloba extract ... - NIH, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2649697/
26. Ginkgo biloba: Health benefits, side effects and risks - Medical News Today, accessed October 29, 2025, https://www.medicalnewstoday.com/articles/263105
27. Chemical structures of Ginkgo biloba terpene trilactones (a bilobalide,... - ResearchGate, accessed October 29, 2025, https://www.researchgate.net/figure/Chemical-structures-of-Ginkgo-biloba-terpene-trilactones-a-bilobalide-b-ginkgolide_fig1_236908586
28. Metabolic Profile and Quantification of Terpene Trilactones and Flavonoids in Ginkgo biloba L. Buds Depending on Physiological Stages - MDPI, accessed October 29, 2025, https://www.mdpi.com/1661-3821/3/1/14
29. Characterization of Ginkgo biloba Leaf Flavonoids as Neuroexocytosis Regulators - NIH, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7221681/
30. Effect of the antioxidant action of Ginkgo biloba extract (EGb 761) on ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3455891/
31. Antioxidant activity, total polyphenol and flavonoid content of Ginkgo... - ResearchGate, accessed October 29, 2025, https://www.researchgate.net/figure/Antioxidant-activity-total-polyphenol-and-flavonoid-content-of-Ginkgo-extract-from_tbl2_340949464
32. The neuroprotective properties of the Ginkgo biloba leaf: a review of ..., accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/8691847/
33. Ginkgo biloba: indications, mechanisms, and safety - PubMed, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/23538078/
34. EGb 761: ginkgo biloba extract, Ginkor - PubMed, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/12757407/
35. What is EGb-761 used for? - Patsnap Synapse, accessed October 29, 2025, https://synapse.patsnap.com/article/what-is-egb-761-used-for
36. Tebonin® | EGb 761 | Tebonin Forte | Medication for Mental Health, accessed October 29, 2025, https://www.schwabepharma-apac.com/Tebonin-Forte-EGb-761-Medication-for-Mental-Health
37. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4259871/
38. Ginkgo (Ginkgo Biloba) - My Doctor Online - Kaiser Permanente, accessed October 29, 2025, https://mydoctor.kaiserpermanente.org/mas/structured-content/Health_Topic_CAM_-_Ginkgo_Biloba_-_Staying_Healthy.xml?co=/regions/mas
39. Community herbal monograph on Ginkgo biloba L., folium, accessed October 29, 2025, https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-ginkgo-biloba-l-folium_en.pdf
40. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in ..., accessed October 29, 2025, https://www.dovepress.com/article/download/19347
41. Pharmacological effects of Ginkgo biloba and its active ingredients ..., accessed October 29, 2025, https://www.tmrjournals.com/public/articleHTML/TMR/TMR20231022001/index.html
42. 7 Ginkgo Biloba Interactions to Be Cautious Of - GoodRx, accessed October 29, 2025, https://www.goodrx.com/well-being/supplements-herbs/ginkgo-biloba-interactions
43. Effects of Ginkgo biloba on cerebral blood flow assessed by ... - NIH, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3163160/
44. Neuroprotective effects of Ginkgo biloba extract - PubMed, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/14523543/
45. Inhibition of platelet activating factor (PAF)-induced aggregation of ..., accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/15693702/
46. Can Ginkgo biloba interfere with anticoagulant or antiplatelet ..., accessed October 29, 2025, https://www.droracle.ai/articles/341461/ginko-biloba-medication-interference
47. (PDF) Ginkgo biloba Extract Inhibits Platelet Activation via Inhibition ..., accessed October 29, 2025, https://www.researchgate.net/publication/282559781_Ginkgo_biloba_Extract_Inhibits_Platelet_Activation_via_Inhibition_of_Akt
48. Fibrinolytic effects of Ginkgo biloba extract - PMC, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2716226/
49. Ginkgo biloba in the Aging Process: A Narrative Review - MDPI, accessed October 29, 2025, https://www.mdpi.com/2076-3921/11/3/525
50. The Proposed Mechanisms of Action for Ginkgo - EBM Consult, accessed October 29, 2025, https://www.ebmconsult.com/articles/ginkgo-biloba-mechanism-of-action-moa
51. Ginkgo biloba extract: mechanisms and clinical indications, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/10807109/
52. Ginkgo biloba extract EGb 761® in the symptomatic treatment of ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6267544/
53. Ginkgo biloba - Alzheimer's Drug Discovery Foundation, accessed October 29, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Ginkgo-biloba-Cognitive-Vitality-For-Researchers.pdf
54. Effects of Ginkgo biloba extract EGb 761® on cognitive control ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5084772/
55. Effects of chronic administration of Ginkgo biloba extract (EGb 761 ..., accessed October 29, 2025, https://www.researchgate.net/publication/312177892_Effects_of_chronic_administration_of_Ginkgo_biloba_extract_EGb_761R_on_levels_of_dopamine_noradrenaline_and_serotonin_in_the_prefrontal_cortex_of_the_awake_rat
56. Mechanisms of Ginkgo biloba on monoaminergic neurotransmission ..., accessed October 29, 2025, https://consensus.app/search/mechanisms-of-ginkgo-biloba-on-monoaminergic-neuro/bx75qxwxS2S4W7iJoB-Ozw/
57. Ginkgo biloba extract (EGb 761) modulates the expression of ..., accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/22885234/
58. Effects of Ginkgo biloba in dementia: systematic review and meta ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2846949/
59. Study Details | NCT00010803 | Ginkgo Biloba Prevention Trial in Older Individuals | ClinicalTrials.gov, accessed October 29, 2025, https://clinicaltrials.gov/study/NCT00010803?term=Ginkgo&viewType=Table&rank=7
60. Study Details | NCT00010803 | Ginkgo Biloba Prevention Trial in Older Individuals, accessed October 29, 2025, https://www.clinicaltrials.gov/study/NCT00010803
61. Commentary: Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis - Journal of Neurology and Neuromedicine, accessed October 29, 2025, https://www.jneurology.com/articles/commentary-ginkgo-biloba-for-mild-cognitive-impairment-and-alzheimer-s-disease-a-systematic-review-and-metaanalysis-of-randomized.pdf
62. Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo ..., accessed October 29, 2025, https://www.mdpi.com/1424-8247/14/4/305
63. Efficacy and adverse effects of ginkgo biloba for cognitive ... - PubMed, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/25114079/
64. Full article: Ginkgo biloba extract EGb 761 is safe and effective in the ..., accessed October 29, 2025, https://www.tandfonline.com/doi/full/10.1080/15622975.2024.2446830?src=exp-la
65. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials - PubMed, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/39895346/
66. Ginkgo Biloba Dosage For Cognitive Function - Consensus ..., accessed October 29, 2025, https://consensus.app/questions/ginkgo-biloba-dosage-for-cognitive-function/
67. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild ..., accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/24633934/
68. Ginkgo biloba for cognitive improvement in healthy individuals - PMC - NIH, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6513461/
69. Modulation of cognitive performance following single doses of 120 ..., accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/17902186/
70. (PDF) Ginkgo biloba as an Alternative Medicine in the Treatment of ..., accessed October 29, 2025, https://www.researchgate.net/publication/311348342_Ginkgo_biloba_as_an_Alternative_Medicine_in_the_Treatment_of_Anxiety_in_Dementia_and_other_Psychiatric_Disorders
71. Ginkgo biloba special extract EGb 761 in generalized anxiety ..., accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/16808927/
72. A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. - DrugBank, accessed October 29, 2025, https://go.drugbank.com/articles/A232389
73. Debunking Medical Myths: Ginkgo Biloba: Does It Relieve Anxiety? - Digital Commons @ Wayne State, accessed October 29, 2025, https://digitalcommons.wayne.edu/cgi/viewcontent.cgi?article=1613&context=pat_edu_proj
74. Effects and safety of Ginkgo biloba on depression: a systematic review and meta-analysis, accessed October 29, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1364030/full
75. From the Cochrane library: Ginkgo biloba for intermittent ..., accessed October 29, 2025, https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000021
76. (PDF) Ginkgo biloba for intermittent claudication (Review), accessed October 29, 2025, https://www.researchgate.net/publication/237202331_Ginkgo_biloba_for_intermittent_claudication_Review
77. Ginkgo biloba for intermittent claudication - PubMed, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/19370657/
78. Ginkgo biloba for intermittent claudication - PubMed, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/23744597/
79. Ginkgo biloba for intermittent claudication - PMC, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6896896/
80. Ginkgo biloba for intermittent claudication - Maastricht University, accessed October 29, 2025, https://cris.maastrichtuniversity.nl/en/publications/ginkgo-biloba-for-intermittent-claudication
81. Ginkgo Biloba extract for the treatment of intermittent claudication: A meta-analysis of randomized trials | Request PDF - ResearchGate, accessed October 29, 2025, https://www.researchgate.net/publication/12308450_Ginkgo_Biloba_extract_for_the_treatment_of_intermittent_claudication_A_meta-analysis_of_randomized_trials
82. Is Ginkgo biloba (Ginkgo) effective for treating tinnitus? - Dr.Oracle, accessed October 29, 2025, https://www.droracle.ai/articles/434325/ginkgo-in-tinnitus
83. Tinnitus | Cochrane Complementary Medicine, accessed October 29, 2025, https://cam.cochrane.org/tinnitus
84. Ginkgo biloba for tinnitus - PubMed, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/23543524/
85. Ginkgo biloba for tinnitus - PMC - PubMed Central - NIH, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6926930/
86. Ginkgo biloba herbal supplement for tinnitus - Cochrane, accessed October 29, 2025, https://www.cochrane.org/evidence/CD013514_ginkgo-biloba-herbal-supplement-tinnitus
87. Avoid Ginkgo Biloba for Tinnitus! | NeuroMed Tinnitus Clinic, accessed October 29, 2025, https://neuromedcare.com/ginkgo-biloba-for-tinnitus/
88. Is Ginkgo Biloba Safe? - Consensus Academic Search Engine, accessed October 29, 2025, https://consensus.app/questions/ginkgo-biloba-safe/
89. Efficacy and safety of Ginkgo biloba standardized extract in the treat ..., accessed October 29, 2025, https://www.dovepress.com/efficacy-and-safety-of-ginkgo-biloba-standardized-extract-in-the-treat-peer-reviewed-fulltext-article-NDT
90. Treatment of dementia and mild cognitive impairment with or without ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6488894/
91. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10041984/
92. A systematic review of clinical trials on Ginkgo (Ginkgo biloba ... - NIH, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8264219/
93. Spontaneous Bleeding Associated with Ginkgo biloba: A Case ... - NIH, accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1490168/
94. Be Cautious with Ginkgo Biloba - Consumer Med Safety, accessed October 29, 2025, https://www.consumermedsafety.org/safety-articles/be-cautious-with-ginkgo-biloba
95. Ginkgo biloba and cerebral bleeding: a case report and critical review, accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/21364361/
96. Spontaneous bleeding associated with ginkgo biloba: a case report ..., accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/16050865/
97. Does Ginkgo biloba increase the risk of bleeding? A systematic ..., accessed October 29, 2025, https://www.researchgate.net/publication/286867621_Does_Ginkgo_biloba_increase_the_risk_of_bleeding_A_systematic_review_of_case_reports
98. Your questions about complementary medicines ... - RACGP, accessed October 29, 2025, https://www.racgp.org.au/getattachment/c6cfca72-e9a3-4c6e-888f-e2f049d8af6a/Your-questions-about-complementary-medicines-answe.aspx
99. Ginkgo Biloba and ibuprofen Interactions - Drugs.com, accessed October 29, 2025, https://www.drugs.com/drug-interactions/ginkgo-biloba-with-ibuprofen-1174-10621-1310-0.html?professional=1
100. Untitled - Center for Science in the Public Interest, accessed October 29, 2025, https://www.cspi.org/sites/default/files/attachment/ginkgo-fda-letter-6-3-2013.pdf
101. Ginkgo Biloba - Women's Health - Associates for Women's Medicine ..., accessed October 29, 2025, https://www.afwomensmed.com/health-library/hw-view.php?DOCHWID=hw136253spec
102. [PDF] Safety and efficacy of ginkgo (Ginkgo biloba) during ..., accessed October 29, 2025, https://www.semanticscholar.org/paper/Safety-and-efficacy-of-ginkgo-(Ginkgo-biloba)-and-Dugoua-Mills/fc7b8fac74be84d31921d7899e54fbf93efba38f
103. Study Details | NCT02425436 | Role of Ginkgo Biloba Extract in ..., accessed October 29, 2025, https://clinicaltrials.gov/study/NCT02425436?term=Ginkgo&viewType=Table&rank=8
104. Ginkgo - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed October 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501809/
105. Ginkgo Biloba and warfarin Interactions - Drugs.com, accessed October 29, 2025, https://www.drugs.com/drug-interactions/ginkgo-biloba-with-warfarin-1174-10621-2311-0.html?professional=1
106. Ginkgo and Warfarin Interaction in a Large Veterans Administration ..., accessed October 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4765589/
107. (PDF) Ginkgo and Warfarin Interaction in a Large Veterans Administration Population, accessed October 29, 2025, https://www.researchgate.net/publication/317067167_Ginkgo_and_Warfarin_Interaction_in_a_Large_Veterans_Administration_Population
108. Impact of Ginkgo biloba drug interactions on bleeding risk and ..., accessed October 29, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0321804
109. Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis - Research journals - PLOS, accessed October 29, 2025, https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0321804&type=printable
110. Herbal supplements and heart medicines may not mix - Mayo Clinic, accessed October 29, 2025, https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/herbal-supplements/art-20046488
111. Impact of Ginkgo biloba drug interactions on bleeding risk and ..., accessed October 29, 2025, https://pubmed.ncbi.nlm.nih.gov/40198642/
112. Ginkgo Biloba: Uses, Interactions & Side Effects - Cleveland Clinic, accessed October 29, 2025, https://my.clevelandclinic.org/health/drugs/18382-ginkgo-capsules-and-tablets
113. Fatal intracerebral mass bleeding associated with Ginkgo biloba ..., accessed October 29, 2025, https://www.researchgate.net/publication/10698753_Fatal_intracerebral_mass_bleeding_associated_with_Ginkgo_biloba_and_ibuprofen_1
114. Complementary medicines Q&A: gingko biloba - RACGP, accessed October 29, 2025, https://www.racgp.org.au/afp/2015/august/your-questions-about-complementary-medicines-answe
115. Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts - Psychiatria Polska, accessed October 29, 2025, https://www.psychiatriapolska.pl/pdf-80998-81502?filename=Unwanted%20effects%20of.pdf
116. Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice. | Semantic Scholar, accessed October 29, 2025, https://www.semanticscholar.org/paper/Ginkgo-biloba-extract-attenuates-warfarin-mediated-Taki-Yokotani/ee16fc34a821be2191e768e5cd116bc3e180a1e1
117. (PDF) Pharmacokinetic drug interactions involving Ginkgo biloba, accessed October 29, 2025, https://www.researchgate.net/publication/250307383_Pharmacokinetic_drug_interactions_involving_Ginkgo_biloba
118. Pharmacokinetic drug interactions involving Ginkgo biloba, accessed October 29, 2025, https://www.tandfonline.com/doi/full/10.3109/03602532.2013.815200
119. (PDF) Effect of Ginkgo biloba special extract EGb 761A (R) on ..., accessed October 29, 2025, https://www.researchgate.net/publication/51906163_Effect_of_Ginkgo_biloba_special_extract_EGb_761A_R_on_human_cytochrome_P450_activity_a_cocktail_interaction_study_in_healthy_volunteers
120. Ginkgo Biloba: Benefits, Side Effects, and Safety Considerations, accessed October 29, 2025, https://www.webmd.com/vitamins-and-supplements/supplement-guide-ginkgo-biloba
121. Ginkgo Biloba Chicago Health European Standardized Extract 120 mg, accessed October 29, 2025, https://chicagohealthfoods.com/products/ginkgo-biloba-extract-120-mg
122. Buy Bulk - Ginkgo Biloba Extract - USP | Jedwards International, accessed October 29, 2025, https://bulknaturaloils.com/ginkgo-biloba-extract-usp-s2075.html
123. GINKGO BILOBA LEAF EXTRACT - Bluebonnet Nutrition, accessed October 29, 2025, https://bluebonnetnutrition.com/products/ginkgo-biloba-leaf-extract
124. Ginkgo Biloba Standardized Extract, 60 mg, 60 Tablets - Lindberg, accessed October 29, 2025, https://www.pipingrock.com/products/ginkgo-biloba-standardized-extract-60-mg-60-tablets-23040
125. What is the maximum dosage of Ginkgo biloba (Ginkgo biloba ..., accessed October 29, 2025, https://www.droracle.ai/articles/114939/maximum-dosage-fo-ginko-biloba
126. Ginkgo Biloba: Side Effects, Uses, Dosage, Interactions, Warnings, accessed October 29, 2025, https://www.rxlist.com/ginkgo_biloba/generic-drug.htm
127. Ginkgo Biloba Dosage Guide: How Much Is Too Much? - GoodRx, accessed October 29, 2025, https://www.goodrx.com/well-being/supplements-herbs/ginkgo-biloba-dosages
128. Indication-specific dosing for Eun-haeng, fossil tree, ginko biloba ..., accessed October 29, 2025, https://reference.medscape.com/drug/eun-haeng-fossil-tree-ginkgo-biloba-344537
129. Ginkgo for Intermittent Claudication | 2001-08-01 |… | Clinician.com, accessed October 29, 2025, https://www.clinician.com/articles/72112-ginkgo-for-intermittent-claudication
130. Blackmores Ginkgo 6000 mg (Tebonin EGb 761) - 30 Tablets for ..., accessed October 29, 2025, https://www.ebay.com/p/3031270246
131. Ginkgo Biloba Uses, Side Effects & Warnings - Drugs.com, accessed October 29, 2025, https://www.drugs.com/mtm/ginkgo-biloba.html
132. Post-market Determinations that the Use of a Substance is not GRAS, accessed October 29, 2025, https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=Postmarket&id=ginkgobiloba
133. Ginkgo folium - herbal medicinal product | European Medicines ..., accessed October 29, 2025, https://www.ema.europa.eu/en/medicines/herbal/ginkgo-folium
134. Regulation of Medicines | Complementary Therapies | %, accessed October 29, 2025, https://www.cancercouncil.com.au/cancer-information/living-well/complementary-therapies/safety-concerns/regulation-of-medicines/
135. Australia's TGA - Global Regulatory Partners, Inc., accessed October 29, 2025, https://globalregulatorypartners.com/countries/tgas-australia/
136. Ginkgo biloba products | Therapeutic Goods Administration (TGA), accessed October 29, 2025, https://www.tga.gov.au/safety-and-shortages/safety-monitoring-and-information/safety-alerts/ginkgo-biloba-products
137. Caution with complementaries for cognitive impairment, accessed October 29, 2025, https://www.nps.org.au/assets/00c654d08804ac7e-b4ed5d115d48-0ed38e2f2da00d850113f4cb243db3025ff6c6998c49e42b544eff23a74a.pdf
138. Blackmores Ginkgo 6000 mg Tebonin EGb 761 (222229 ..., accessed October 29, 2025, https://www.tga.gov.au/resources/artg/222229
139. BLACKMORES GINKGO 6000 mg TEBONIN® EGb 761 ..., accessed October 29, 2025, https://www.blackmores.com.au/-/media/au/products/ginkgo-6000mg/cmi-ginkgo-tebonin-final-03-may-2023.pdf
140. Blackmores Ginkgo 6000 mg (Tebonin® EGb 761®), accessed October 29, 2025, https://www.blackmores.com.au/products/ginkgo-6000mg
141. GINKGO - precisionFDA, accessed October 29, 2025, https://precision.fda.gov/ginas/app/ui/substances/19FUJ2C58T